Reported Saturday, Acrivon Therapeutics Reports ACR-368 Phase 2 Endometrial Cancer Data At ESMO, Advances ACR-2316 Ahead Of Schedule, And Updates On AP3 Interactome Progress
Portfolio Pulse from Benzinga Newsdesk
Acrivon Therapeutics reported promising Phase 2 data for ACR-368 in endometrial cancer, showing a 62.5% response rate in selected patients. The company is advancing ACR-2316 ahead of schedule and making progress with its AP3 Interactome. A webcast with Dr. Ramez N. Eskander is scheduled.
September 16, 2024 | 8:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acrivon Therapeutics' ACR-368 shows a 62.5% response rate in endometrial cancer, potentially leading to accelerated regulatory approval. ACR-2316 progresses ahead of schedule, and AP3 Interactome provides actionable insights.
The high response rate of ACR-368 in endometrial cancer and the potential for accelerated approval are positive indicators for Acrivon Therapeutics. Advancing ACR-2316 ahead of schedule and progress in AP3 Interactome further strengthen the company's position.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100